• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Financial Services·RAFI
Share

Regency Affiliates, Inc. Stocks

$ 4.3Last Updated 27.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 19.28M

$ 4.3
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Regency Affiliates, Inc. (RAFI) operates in two main sectors. Firstly, it possesses an equity interest in MESC Capital, LLC, which in turn manages an on-site power generation plant. This facility is responsible for supplying approximately 61 megawatts of both steam and electricity to a Kimberly-Clark tissue manufacturing facility located in Mobile, Alabama. Secondly, RAFI holds and maintains a significant real estate asset in Woodlawn, Maryland, through a limited partnership. This property includes 34.3 acres of land and roughly 717,000 square feet of rentable commercial space. The commercial property comprises a two-story office building that is directly connected to a six-story office tower. The company's primary corporate office is situated in New York, New York.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 00:34

A War Between the U.S. and Iran Could Drag On for Several Months — Bloomberg

30.07.2026 00:08

Google has disbanded its Nobel Prize-winning team. Some of its members will join Anthropic

29.07.2026 23:01

The Fed has kept interest rates unchanged for the fifth consecutive time. What's next?

29.07.2026 22:23

"It's a Matter of Lost Trust": Chipmakers Lost More Than $1 Trillion in Market Capitalization in Two Days

29.07.2026 22:06

Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026